Archive · 4 Oct 2025
Adar Poonawalla's Business Ventures: From Vaccines to Sports
Adar Poonawalla, the head of a big vaccine company, made smart moves during the pandemic by quickly making a COVID-19 vaccine.
This made his company a lot of money.
Now, he's expanding into different areas like buying a stake in a film company and possibly an IPL cricket team.
He's also investing in other companies and working on new vaccines.
Poonawalla is known for taking calculated risks and making investments, not just in vaccines, but in other businesses too.
These moves aim to grow his business further.
Adar Poonawalla is reportedly in talks to buy the Royal Challengers Bengaluru (RCB) IPL team.
Serum Institute of India (SII) partnered with AstraZeneca to manufacture the Covishield vaccine during the pandemic.
SII's revenue increased nearly fivefold from FY20 to FY22 due to the vaccine.
Poonawalla acquired a 60% stake in Magma Fincorp, now Poonawalla Fincorp.
He invested in film production, acquiring 50% stake in Dharma Productions.
- Who
- Adar Poonawalla, CEO of Serum Institute of India
- What
- Poonawalla's business ventures including vaccine production, finance, and film production
- When
- Key ventures occurred between 2020 and 2024
- Where
- Based in India, with global reach through SII
- Why
- Diversification and seizing opportunities.
- Company
- Serum Institute of India (SII)
- Key Person
- Adar Poonawalla
- Recent Venture
- Potential acquisition of Royal Challengers Bengaluru (RCB)
- SII Revenue (FY22)
- Rs 25,645 crore
- Stake in Dharma Productions
- 50%
- Investment in Biocon Biologics
- $300 million